EXHANCE-12: A One Year Study of Safety and Efficacy of a Fluticasone Propionate Exhalation Delivery System (FLU-EDS), in Patients with Chronic Rhinosinusitis With and Without Polyps

BACKGROUND

- Chronic Rhinosinusitis with (CRSwNP) and without (CRSsNP) nasal polyps is common (11.5-27.9 million persons in the U.S.) and is associated with substantial disease burden. The overall annual economic burden of CRS in the U.S. was estimated to be $22 billion (direct and indirect costs) in 2014.1,2
- Cardinal symptoms include nasal congestion obstruction, rhinorrhea, facial pain/pressure, and reduction/loss of smell. Extranasal manifestations are very common and include fatigue and bodily pain, sleep dysfunction, and depression. The overall effect is an impairment of quality of life (QoL) similar in degree to serious diseases such as CHF, COPD, and Parkinson’s.3,4
- Inflammation is a hallmark of CRS and is generally present throughout the sinonasal cavities, inclusive of the ostiomeatal complex (OMC), where the sinus ostia drain and ventilate. Nasal polyps most commonly originate in this area.5
- Intranasal corticosteroid (INCS) sprays are part of standard of care in all treatment guidelines; however, conventional INCS are relatively inefficient and ineffective in delivery of topically-acting drug to key disease sites beyond the nasal valve area, including the OMC, potentially reducing treatment benefit, and are associated with low treatment satisfaction.2
- Exhalation Delivery Systems (EDS) (Figure 1) have been shown to deposit drug deeper and more broadly in the nasal cavity (particularly superiorly/posteriorly; e.g., OMC), with less drug loss to drip-out and swallowing, compared to conventional INCS. FLU-EDS (fluticasone propionate exhalation delivery system) uses a novel EDS to substantially modify delivery of locally-acting steroid (fluticasone), including to the OMC.6,7
- The objective of this study was to assess the long-term safety and efficacy of FLU-EDS 372 µg twice daily (BID) in patients with moderate-severe CRS, with or without nasal polyps.

METHODS

- 52-week open-label, multicenter, repeated endoscopy study
  - Eligible patients were ≥18 years of age with CRSwNP/sNP, as determined by nasonpasscopy plus history of diagnostic symptoms for ≥12 weeks, and were currently experiencing 22 core symptoms of CRS, one of which had to be nasal congestion obstruction or rhinorrhea.

RESULTS

- 333 patients were screened, and 224 patients were enrolled at 21 centers in the U.S. 223 patients received study drug of which 144 (64.6%) completed the study.
- Baseline characteristics are shown in Table 1.

Table 1. Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>CRSwNP (n=34)</th>
<th>CRSsNP (n=189)</th>
<th>Safety Set (n=223)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>46 (13.7)</td>
<td>45.3 (12.5)</td>
<td>45.4 (12.6)</td>
</tr>
<tr>
<td>Male sex, No. (%)</td>
<td>20 (58.8)</td>
<td>76 (40.2)</td>
<td>96 (43)</td>
</tr>
<tr>
<td>White race, No. (%)</td>
<td>30 (88.2)</td>
<td>145 (76.7)</td>
<td>175 (78.5)</td>
</tr>
<tr>
<td>Clinicians used for CRS in last 10 yrs, No. (%)</td>
<td>34 (100)</td>
<td>180 (95.2)</td>
<td>214 (96)</td>
</tr>
<tr>
<td>Bilateral nasal polyp score, mean (SD)</td>
<td>2.8 (1.17)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lund-Mackay total score, mean (SD)</td>
<td>1.7 (1.5)</td>
<td>1.4 (1.2)</td>
<td>1.4 (1.3)</td>
</tr>
<tr>
<td>SNOT-22 total score, mean (SD)</td>
<td>41.9 (23.3)</td>
<td>39.7 (21.7)</td>
<td>40 (21.9)</td>
</tr>
<tr>
<td>≥1 sinus surgery for polyp removal or sinus surgery, No. (%)</td>
<td>15 (44.1)</td>
<td>49 (25.9)</td>
<td>64 (28.7)</td>
</tr>
</tbody>
</table>

Efficacy Assessments

- Lund-Mackay endoscopic assessment
- Nasal Polyp Grading Scale (CRSwNP patients)
- Sino-Nasal Outcome Test (SNOT-22)
- Surgical intervention assessment
- Medication evaluation questionnaire
- Patient Global Impression of Change (PGIC)

Safety Assessments

- Adverse Events (AEs)
- Nasal endoscopy
- Ocular examination by Ophthalmologist
- Clinical laboratory parameters
- Vital signs
- Physical examination

For patients with endoscopic Lund-Mackay edema scores ≥0 at baseline, FLU-EDS treatment was associated with complete resolution of edema in 50% of CRSwNP and 56% of CRSsNP patients at end-of-study (Figure 3)

For CRSwNP, the percentage observed endoscopically to have polyp elimination in at least one nostril increased steadily through 12 months. Among those completing 12 months of treatment, 54.2% had polyp elimination in at least one nostril. (Figure 4)

Following 1 month of FLU-EDS treatment, 54.5% of patients with nasal polyps experienced at least one point improvement in polyp grade. This increased to 83.3%, after 12 months of treatment. (Figure 5)

CONCLUSIONS

- FLU-EDS 372 µg BID substantially improved subjective symptoms and objective local signs of disease with a magnitude of improvement similar in CRS patients with and without nasal polyps.
- Patients with nasal polyps at baseline experienced extensive reduction in polyp grade that continued to improve throughout the follow-up period.
- The AEs reported were generally local in nature, tended to be mild in severity, and were largely transient. AEs did not increase in frequency or severity with increasing duration of exposure to study drug.
- In patients with moderate to severe CRS (with and without polyps) and frequent past use of conventional INCS sprays, FLU-EDS was well tolerated and significantly improved symptoms and objective measures of disease, indicating the important role of superior/posterior drug delivery via EDS.

References:

Contact: John Messina, PhD, OptiNose US Inc., Yardley, PA, USA. Phone: 267-384-7000